Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, ...
Faced with a slumping stock and growing competition in the next-generation sequencing market it continues to dominate, Illumina this past week committed to delivering high single-digit revenue ...
Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, ...
Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- ...
On Monday, Illumina, Inc. (NASDAQ:ILMN) agreed to acquire Standard BioTools’ (NASDAQ:LAB) subsidiary, SomaLogic. Following the announcement of the acquisition, Standard BioTools’ stock experienced a ...
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed ...
Illumina, Inc. ILMN recently announced the launch of Illumina Protein Prep, an assay designed to deliver superior performance for next-generation sequencing (NGS)-based proteomics discovery at scale.
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Illumina, a leader in DNA sequencing and array-based technologies, offers a promising new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results